Active Pharmaceutical Ingredients (API), popularly speaking, are the raw materials of medicines, only pharmaceutical raw materials are processed into pharmaceutical preparations , can they become medicines available for clinical use, so drugs we usually eat are the finished drugs through processing. Active Pharmaceutical Ingredients based on its sources can be divided into two major categories ,including chemical synthetic drugs and natural chemical drugs. Chemical synthetic drugs can be divided into organic synthetic drugs and inorganic synthetic drugs. Inorganic synthetic drugs are inorganic compounds ( very few is element), such as aluminum hydroxide, magnesium trisilicate which are used for the treatment of gastric and duodenal ulcers ; organic synthetic drugs are mainly composed of drugs made by basic organic chemical raw materials, through a series of organic chemical reactions (such as aspirin, chloramphenicol, caffeine, etc.). Natural chemical drugs ,based on its sources,can be divided into two categories including biochemical drugs and plant chemical drugs. Antibiotics are generally made by the microbial fermentation, which belongs to the biochemistry category. A variety of semi-synthetic antibiotics occurs in recent years,which are biosynthesis and chemical synthesis combining products.Among active Pharmaceutical Ingredients, the organic synthetic drugs varieties, yields and values have the largest proportion,which are the main pillars of the chemical and pharmaceutical industries. The quality of active Pharmaceutical Ingredients decides whether the formulation is good or bad , so its quality standards are very strict ,countries in the world have developed national pharmacopoeia standards and strict quality control methods for its widely used active Pharmaceutical ingredients.
Q:What is the daily intake of Pyrroloquinoline quinone disodium salt? When is the best time to take it?
A:Pyrroloquinoline quinone disodium salt is the disodium salt form of Pyrroloquinoline quinone (PQQ) and has similar effects and benefits to PQQ.
Mar 24,2025 APIAcalabrutinib:Brand name, FDA approval, Indications and Side effects
Acalabrutinib is an oral inhibitor of Bruton's tyrosine kinase that is used in the therapy of B cell malignancies including refractory mantle cell lymphoma and chronic lymphocytic leukemia.
Mar 24,2025 APIWhat to know when taking Vandetanib?
Vandetanib works by blocking the action of abnormal proteins that signal cancer cells to multiply, thereby helping to slow or stop the spread of cancer cells.
Mar 24,2025 APIPyrroloquinoline quinone: Food sources, benefits and side effects
Pyrroloquinoline quinone (PQQ) is a quinone described as a cofactor for many bacterial dehydrogenases and reported to have effects on mammalian cell/tissue metabolism.
Mar 24,2025 APIFDA-approved drug Tofacitinib citrate: Brand name,Indications and Side Effects
Tofacitinib citrate is a Janus kinase (JAK) inhibitor, it treats adults with moderate to severe rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, and moderate to severe
Mar 24,2025 APIMirogabalin besylate:Indications, Advantages,Mechnaism of action and Side effects
Mirogabalin besylate is indicated for patients with peripheral neuropathic pain and central neuropathic pain after spinal cord injury and stroke, many of whom are elderly.
Mar 24,2025 APIMacitentan: a dual endothelin-receptor antagonist
Macitentan is an orally active, non-peptide, potent dual ERA and macitentan selectively inhibits the binding of endothelin-1 (ET-1) to ETA and ETB receptors.
Mar 24,2025 APIJAK inhibitor Upadacitinib:FDA approval,Brand name,Indications and Side effects
Upadacitinib received FDA approval on August 16, 2019, based on positive and promising results from its multinational phase III trials in subjects with moderate to severe rheumatoid arthritis.
Mar 24,2025 APISelpercatinib (LOXO-292):Indications, Mechnaism,Clinical trials and Side effects
Selpercatinib (LOXO-292) is a highly selective RET inhibitor with activity across known oncogenic RET fusions and mutations.
Mar 21,2025 APIFruquintinib:Indications,Trials and Side effects
Fruquintinib, as an oral tyrosine kinase inhibitor (TKI), effectively suppresses vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR) signaling and inhibits cell
Mar 21,2025 API